Compare AbCellera Biologics Inc (ABCL) vs Amplify Transformational Data Sharing ETF (BLOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Amplify Transformational Data Sharing ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Amplify Transformational Data Sharing ETF trades at $62.02. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | BLOK | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $74.10 |
52-Week Low | $2.78 | $47.36 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BLOK trades at $63.47, up 3.07% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock faces resistance at $64 and support at $62. Recent news highlights the ETF's exposure to AI infrastructure and Bitcoin mining stocks, though analyst sentiment has turned cautious due to increased crypto market correlation.
The outlook remains neutral with technical indicators divided and fundamental data limited. Key risks include reliance on volatile crypto markets and competitive ETF pressures. Analyst consensus suggests holding pending clearer catalysts from AI infrastructure growth or Bitcoin market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Amplify Transformational Data Sharing ETF
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →
